Predicting Neoadjuvant Chemotherapy Response by Using a Combined MRI and Scinti-Mammography (MRI-SMM) System

Completed

Conditions studied: Breast Cancer

In brief

The purpose of this research study is to investigate the accuracy of a breast imaging system that measures the uptake of the injected radioactive tracer by gamma-ray imaging, known as scinti-mammography (SMM), to diagnose the residual breast cancer after neoadjuvant chemotherapy (NAC) treatment by comparing to MRI.

Key facts

Study ID

NCT02690805

Run by

University of California, Irvine

People needed

16

Starts

2015-05-01

Expected to finish

2019-01-25

Last updated by the study team

2021-04-19

Who can join

Age: 21 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• A female older than 21 years of age,
• Have biopsy-proven breast cancer and decided to receive neoadjuvant chemotherapy.
• Are in good health (other than having breast cancer) and can lie still in a prone position for 45 minutes inside MRI scanner.

You may not qualify if…

• Pregnant,
• Unwilling to give informed consent,
• Have implanted prosthetic heart valves, pacemaker, neuro-stimulation devices, surgical clips (hemostatic clips) or other metallic implants,
• Have engaged in occupations or activities which may cause accidental lodging of ferromagnetic materials (e.g. iron), or have imbedded metal fragments from military activities,
• Have received orthodontic work involving ferromagnetic materials,
• Claustrophobic (i.e. feeling very anxious in a confined small space),
• Have had allergic response to contrast agents (such as iodine or gadolinium) previously,
• Have known history of kidney diseases.

Where it is running

• University of California — Irvine, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.